A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met.